Santarus Uceris Launch To Include Heavy Copay Assistance For First Six Months
This article was originally published in The Pink Sheet Daily
The San Diego biotech plans to add 85 reps to its sales force in preparation for a launch in March following approval of its ulcerative colitis drug.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.